Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

$6.1 million for the same period in 2007.

For the three months ended December 31, 2008, Micromet reported a net loss of $5.9 million, or $0.12 per basic and diluted common share, compared to a net loss of $3.8 million, or $0.09 per basic and diluted common share, for the same period in 2007.

Year Ended December 31, 2008

For the year ended December 31, 2008, Micromet recognized total revenues of $27.3 million, compared to $18.4 million for 2007. Total operating expenses were $53.4 million for the year ended December 31, 2008, compared to $43.6 million for 2007.

Loss from operations for the year ended December 31, 2008 was $26.1 million, compared to the $25.2 million loss from operations in 2007.

For the year ended December 31, 2008, Micromet reported a net loss of $33.2 million, or $0.77 per basic and diluted common share, compared to a net loss of $20.1 million, or $0.55 per basic and diluted common share, for 2007. The net loss for the year ended December 31, 2008 includes a non-cash charge of $8.1 million, reflecting an increase during the year in the fair value of warrants that we issued in a 2007 private placement transaction, compared to a $1.8 million non-cash gain for this item in 2007. The fair value of the warrants is calculated based on the Black-Scholes model. Increases in our stock price during a reporting period result in a non-cash expense, while decreases in our stock price during a reporting period result in non-cash income.

Net cash used in operating activities was $15.7 million for the year ended December 31, 2008 compared to $14.3 million used in operating activities for 2007. Micromet's cash and cash equivalents were $46.2 million as of December 31, 2008.

Conference Call and Audio Webcast Today, March 12, 2009, at 9:00 am U.S. Eastern Time.

To participate in this conference cal
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Today, TiFiber, Inc. ... facility and future company headquarters in Fort Smith, ... materials that safely and effectively control dangerous microorganisms. ... its historic, strong support for manufacturing, but also ... edge, technology-based companies such as TiFiber. , ...
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
(Date:12/19/2014)...  Decision Resources Group finds that the ... moderately through 2023 as the aging population, increasing adoption ... biomaterials all spur procedure volumes. Growth will be particularly ... and India , where ... for a larger proportion of the population. ...
(Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3
... , May 27 Medivation, ... of its public offering of 2,750,000 shares of its common ... The company expects to complete the sale of these shares ... the underwriters a 30-day option to purchase 412,500 additional shares ...
... (Nasdaq: BLUD ), a global leader ... transfusion industry, announced today that it has signed ... one of the largest regional hospital laboratory integrated ... in Illinois and Indiana. Under the agreement, Alverno ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... partner, Boston Scientific Corporation (NYSE: BSX ... and Drug Administration (FDA) to market its TAXUS(R) ... deliverable, next-generation drug-eluting stent (DES) specifically designed for ...
Cached Biology Technology:Medivation Announces Pricing of Public Offering 2Immucor and Alverno Clinical Laboratories Sign Five-Year Automation Agreement 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 2Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 3Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 4Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system 5
(Date:12/17/2014)... FORT BELVOIR, Va. , Dec. 15, 2014 ... its efforts to make it easier to detect ... supply chain. Today the agency started ... marking. The capability will validate the authenticity of ... supply chain. The new quality control measures will ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... were dubious in the early 1980s when they stumbled on ... only were they not supposed to be there, but they ... from proteins, effectively switching them on and off. The ... and off -- and thus determining their actions -- fell ...
... St. Louis, Oct.20, 2008 Researchers have shown that self-induced ... activate genes that cause the cells to travel from where ... Scientists have known for two decades or more ... creating splits in both of the two strands. However, the ...
... COLUMBUS, Ohio Reducing the number of deer in ... reptiles, amphibians and insects in that area, new research ... Ohio State University and National Park Service found that ... ways. Out of several species of snakes, salamanders, and ...
Cached Biology News:Johns Hopkins researchers detect sweet cacophony while listening to cellular cross-talk 2Seemingly suicidal stunt is normal rite of passage for immune cells 2Seemingly suicidal stunt is normal rite of passage for immune cells 3Snakes, salamanders and other creatures thrive in areas with higher deer populations 2Snakes, salamanders and other creatures thrive in areas with higher deer populations 3
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... microcapillary flow cytometry accessible to anyone in ... appreciate the latest addition to Guavas on-demand ... surprising affordable, and very compact for higher ... features as absolute cell counts, 6 parameters ...
...
Biology Products: